The American Society of Clinical Oncology released its first guidance statement on the cost of cancer care in August 2009, affirming that patient-physician cost communication is a critical component of high-quality care. This forward-thinking recommendation has grown increasingly important in oncology practice today as the high costs of cancer care impose tremendous financial burden to patients, their families, and the health care system. For the current review, a literature search was conducted using the PubMed and Web of Science databases to identify articles that covered 3 topics related to patient-physician cost communication: patient attitude, physician acceptance, and the associated outcomes; and 15 articles from 12 distinct studies were identified. Although most articles that addressed patient attitude suggested that cost communication is desired by >50% of patients in the respective study cohorts, only <33% of patients in those studies had actually discussed costs with their physicians. The literature on physician acceptance indicated that, although 75% of physicians considered discussions of out-of-pocket costs with patients their responsibility, <30% felt comfortable with such communication. When asked about whether cost communication actually took place in their practice, percentages reported by physicians varied widely from <10% to >60%. The data suggested that cost communication was associated with improved patient satisfaction, lower out-of-pocket expenses, and a higher likelihood of medication nonadherence; none of the studies established causality. Both patients and physicians expressed a strong need for accurate, accessible, and transparent information about the cost of cancer care. Cancer 2017;123:928-39.
INTRODUCTION
Therapeutic advances in oncology have improved the survival of patients with cancer. However, clinical improvements achieved by new oncologic treatments often come with a high price tag. Numerous researchers cautioned about the high cost of cancer drugs when targeted therapy agents first became available in the United States, noting that agents like trastuzumab could increase the cost of chemotherapy by $50,000 for patients with breast cancer 1 and that the combination of irinotecan and cetuximab would push the cost of a full course of chemotherapy to $160,000 for patients with colorectal cancer. 2 Thus, as the price of cancer drugs continues to rise, the financial burden of cancer care grows increasingly worrisome. 3, 4 Driven by the concern that rising costs can threaten the affordability of high-quality cancer care, the American Society of Clinical Oncology (ASCO) established a Cost of Care Task Force in 2007. That task force published a guidance statement on the cost of cancer care in 2009, marking 1 of the first official efforts from a specialty society to affirm patientphysician cost communication as a key component of high-quality care. 5 The importance of cost communication was also emphasized in a 2013 Institute of Medicine report on cancer care quality. 6 Although the ASCO cost-of-cancer-care guidance statement is well reasoned, concerns have been voiced that patients may feel uncomfortable discussing the costs of their treatment options with physicians. 7 Similar concerns were shared among physicians, who felt ill prepared to undertake a dialogue involving costs. 8, 9 To achieve cost transparency through patient-physician cost communication, it is necessary that the key stakeholders (patients, their families, and health care providers) are willing to engage in this conversation. For the current report, we performed a comprehensive literature review of articles published after the release of the guidance statement from the ASCO Cost of Care Task Force to better understand the attitudes toward and actual conduct of cost communication among patients with cancer and oncologists. We also identified studies that assessed the association between cost communication and various outcomes measures.
MATERIALS AND METHODS
To better understand the role of "cost communication" in cancer care, we conducted a literature search in May 2016. Our inclusion criteria were peer-reviewed, Englishlanguage, full-text articles with information regarding patients' and/or health care providers' communication about the cost of cancer care. We focused on articles published after the ASCO Cost of Care Task Force released its guidance statement in August 2009. An initial search strategy with (cost communication) AND (cancer) as search terms yielded 6 articles published since August 2009, a strikingly small number considering the level of interest in and the importance of this topic. We thus developed a more aggressive search strategy to maximize the number of articles identified by using 2 online databases: PubMed and Web of Science (WoS).
Our search strategy started with a PubMed search. We applied search filters with the following search terms: (cancer) AND ((discuss* On the basis of the assumption that the ASCO Cost of Care Task Force guidance statement would ignite the cancer community's interests in cost communication, we then searched the WoS for articles that cited the task force guidance statement. 5 After removing duplicates and nonEnglish articles, we independently selected potentially relevant studies for the current report after reviewing the titles and abstracts. Articles to be included in this report were determined based on full-text reviews, and disagreements were resolved through discussions.
We summarized the articles included in our review under 3 themes: 1) studies that explored patients' attitudes toward cost communication, 2) studies of physicians' acceptance of cost communication, and 3) studies that reported outcomes (eg, medication adherence, patient satisfaction) associated with cost communication. We synthesized information retrieved from studies under each theme in 3 summary tables with the following common elements: i) authors, year of publication, and country; ii) population and characteristics; iii) site; iv) sample size; v) percentage of study participants who expressed a desire to discuss costs; vi) percentage of study participants who actually discussed costs; and vii) comments that highlight other key components of each study. For elements v and vi, which were the 2 primary outcomes of interests in our review, we included the exact question that was asked in the summary tables (see online supporting information). We reported the weighted means (weighted by the study sample size), medians, and ranges in our synthesis of the literature. For the summary table of studies under theme 3, we replaced element v above with a column that described outcomes associated with cost communication. These elements were adopted, with modifications, from a previous study that surveyed patients with breast cancer to understand their attitudes toward addressing costs. 10 
RESULTS
We depicted our literature search process using a flowchart suggested by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Fig. 1) . 11 In our initial search of PubMed and WoS, 661 articles were identified. After removing duplicate or non-English studies and reviewing the titles and abstracts to remove irrelevant studies from the remaining articles, 53 were left for full-text reviews. Further exclusion of articles that did not meet our inclusion criteria after the full-text reviews resulted in a total of 15 articles to be included herein. These articles covered 12 distinct studies, because research teams sometimes published multiple articles from 1 study. Of the 15 articles, 2 were developed from the same survey of medical oncologists in the United States and Canada, 9,12 2 were from a survey of a convenient sample of 300 patients with cancer, 13, 14 and another 2 were from retrospective analyses of transcribed dialogue collected from >1500 outpatient encounters. 15, 16 Some studies covered more than 1 theme (Supporting Table 1 ; see online supporting information). For example, the study by Kelly et al touched on both patients' and physicians' attitudes toward cost communication and the associated outcomes. 17 
Patient Attitude
Twelve articles from 10 distinct studies investigated patient attitudes regarding cost communication 10, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] ( Table 1 and Supporting Table 2 ; see online supporting information). Nearly all studies took place in the United States, except for 1 Australian study. 18 Information was collected from questionnaires in 7 studies and from semistructured interviews in 2 studies, 21, 23 and another study collected information from a content analysis of transcribed dialogue from audio-recorded clinical encounters. 15, 16 The median sample size was 133 participants, ranging from 22 (a qualitative analysis) 21 to 677 (encounters in breast cancer clinics) 15, 16 . Over one-half of these studies recruited participants from patients with cancer who were currently receiving or had previously received treatment in academic cancer centers or their affiliated oncology clinics. 10, 13, 14, 17, 20, 22, 23 Three studies focused on breast cancer, 10, 15, 16, 18 1 focused on prostate cancer, 23 and others did not focus exclusively on a specific cancer. Most studies were not restricted to a particular cancer stage, except for 1 that focused on metastatic cancers. 17 Sociodemographic characteristics of the participants in these studies reflected more affluent study cohorts. Of the 8 studies that reported patients' income levels, in 7 studies, more than one-half of participants reported an annual income level >$50,000, which was close to the 2014 median annual household income of $53,657 reported by the US Census Bureau. 24 In only 1 study did the majority of patients (78%) report an annual household income <$40,000; however, this was driven by the study's focus on insured patients with cancer who requested copayment assistance. 22 It is noteworthy that the lowest rate of insured individuals (77%) was observed in the Australian study 18 ; all US studies reported high rates of insurance (98%). Six studies (7 articles) asked patients with cancer about financial distress, 10, 13, 14, [19] [20] [21] [22] and the reported percentages ranged from 16% 13, 14 to 47%. 19 Seven studies (8 articles) ascertained patients' attitudes toward cost communication. 10, 13, 14, [17] [18] [19] [20] 23 The mean (weighted) and median proportions of patients who were surveyed or interviewed and expressed a positive attitude toward cost discussions were 60% ( Fig. 2) and 61%, respectively, and ranged from 20% 19 to 96%.
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Of those, 6 studies reported that more than one-half of study participants were in favor of cost communication.
Eight studies (10 articles) inquired whether patients with cancer actually had discussed costs with their physicians. 10, [13] [14] [15] [16] [17] [18] [19] 21, 22 The mean (weighted) and median proportions of patients who had such conversations were 27% ( Fig. 2) and 25%, respectively, and ranged from 14% 10 to 58%. 22 All but 1 study reported that less than one-third of their study participants had discussed costs with their physicians. The high percentage reported by Zafar et al 22 likely reflected their study's focus on insured patients with cancer who sought copayment assistance.
Physician Acceptance
Five studies (7 articles) reported physician acceptance regarding cost communication (Table 2 and Supporting  Table 3 ; see online supporting information). 9, 12, [15] [16] [17] 21, 25 Three studies (4 articles) also explored patient attitudes, as detailed above. All studies included oncologists in the United States, and 1 surveyed both US and Canadian oncologists. 12 Information was collected from selfadministered questionnaires in 2 studies, 9,12,25 from interviews in another 2 studies, 17, 21 and 1 from transcribed dialogue of audio-recorded clinical encounters in 1 study. 15, 16 Two studies recruited study participants by contacting members of ASCO, 9,12,25 and 1 included only oncologists in an academic setting. 17 Although all studies included oncologists, 1 focused exclusively on medical oncology, 9, 12 and another also added a physician assistant to the interview pool. 21 The sample size varied from 11 participants in a more qualitative study 21 to 925 in a large-scale survey. 9, 12 Two studies inquired about physician comfort level toward cost communication; 1 reported that 28% felt comfortable with it, 17 and another indicated that 75% of physicians considered it their responsibility to discuss outof-pocket costs with their patients when making treatment decisions. 25 No weighted mean was reported because of the vast difference in sample size between the 2 studies (18 vs 333). Three studies asked physicians whether cost communication was frequent in their practice, and the proportion reporting that they always or frequently discussed costs with their patients ranged from 6% 17 to 60%, 25 with a weighted mean of 47% (Fig. 2) . The study that analyzed dialogue at encounter level reported that 22% of the visits included cost conversations. 15, 16 Another small sample study (n 5 11) asked physicians about the frequency of cost communication, and the reported percentage varied widely, from 5% to 66%. 21 Two studies investigated the correlation between costs and treatment recommendation. 9, 12, 25 In 1 study, 94% of physicians said that physicians should offer all treatment options regardless of costs. 25 In another study, from 52% (Canadian oncologists) to 67% (US oncologists) of physicians believed that patients should have access to effective cancer drugs regardless of costs. 12 Those 2 studies also revealed that physicians were cost conscious.
In 2010, Berry et al reported that 84% of oncologists in the United States and 80% in Canada believed that outof-pocket costs affected their treatment recommendation 12 ; whereas, in 2016, Altomere et al reported that 79% of physicians agreed that the cheaper option should be chosen when 2 treatments were equally effective. 25 
Outcomes
Three articles (from 2 studies) explored the association between patient-physician cost communication and 3 13 and out-of-pocket costs 14 (Table 3) . Both were US studies, and the study participants were recruited primarily from academic cancer centers and/or the affiliated oncology clinics. Participants in both studies were insured patients with cancer, and >50% had an annual household income >$60,000.
Kelly et al asked oncologists in an academic setting to discuss financial difficulties with their patients at the end of their clinical encounters. 17 In their study, cost information was provided using eviti ADVISOR, a Webbased oncology decision support platform (eviti Inc, Philadelphia, Pa). Assessment of patient satisfaction ratings regarding cost communication revealed that 80% of patients had no negative feelings about hearing cost information, suggesting that the majority of patients considered cost communication satisfactory. Bestvina et al analyzed the association between cost discussions and medication nonadherence and reported that cost discussions were associated with higher odds of medication nonadherence (odds ratio, 2.58; 95% confidence interval, 1.14-5.85). 13 By using data from the same survey, Zafar et al demonstrated that, among the 19% of patients who discussed costs with their physicians, 57% reported lower out-of-pocket costs as a result of that discussion. 14 
DISCUSSION
This report provides a comprehensive literature review on 3 topics of patient-physician cost communication in the context of cancer care: patient attitude, physician acceptance, and outcomes associated with such communication. We identified 15 articles that covered at least 1 of these topics. Collectively, the results from our review suggest that, although cost communication was desired by more than one-half of patients in most study cohorts, less than one-third of patients had actually discussed costs with their physicians. The combined literature also indicated that, although 75% of physicians considered it their responsibility to discuss out-of-pocket cost with patients, <30% felt comfortable with such communication. When asked whether cost communication actually took place, the percentages reported by physicians varied widely across studies, from <10% to >60%. Furthermore, cost communication was associated with improved patient satisfaction, lower out-of-pocket expenses, and a higher likelihood of medication nonadherence; the exact reason(s) and possible causal pathway(s) influencing the latter observation remain enigmatic.
Patient-physician cost communication can potentially improve cost transparency from the patients' Only numbers related to breast cancer were subtracted for both studies.
b Cost/coverage included discussion of patients' OOP costs or insurance coverage.
c COI included discussion of financial costs or insurance coverage related to health or health care.
perspective. A critical element to achieving this is to have accurate cost information, including insurance policies and coverage details. Specifically, whereas patients and their families look to their physicians to help them better understand the cost implications of their treatment choices, physicians who are willing to undertake this challenging task need to have accessible and comprehensible cost information to facilitate the discussion. One study documented that, although >50% of patients expressed some desire to discuss out-of-pocket costs, 76% believed that their physicians had no such knowledge. 13, 14 Indeed, 2 studies reported that physicians lacked knowledge of or accessibility to cost information, which was a major barrier to cost communication. 21, 25 Several Web-based sources have been developed to provide estimates of cancer care costs. For example, eviti ADVISOR was used by Kelly et al to assist oncologists in discussing costs, 17 and DrugAbacus (Memorial Sloan Kettering Cancer Center, New York, NY) offers an interactive tool online to allow consumers to compare prices of cancer drugs. It should be noted that neither source builds in the capability to customize their cost calculations by insurance benefit design. Therefore, cost information obtained from these sources does not directly inform patients of their out-of-pocket expenses and may be of limited use in improving cost transparency through patient-physician cost communication.
The wide range (from 20% to 96%) in the proportion of patients who express a positive attitude toward patient-physician cost communication may reflect differences across studies in the specific question that was asked. In our review, questions related to the topic of "patient attitude" can be broadly categorized into 2 types: those asking whether patients "want to" or "would like to" discuss cost with their physicians 13, 14, 20, 23 versus those asking whether patients "should be" or "wished to be" informed. 10, [17] [18] [19] Studies that asked the first type of questions reported percentages in the 50% to 60% range, whereas those that asked the second type of questions tended to report high percentages, except for the 20% reported in 1 study that asked whether patients should receive cost information from their oncologists. 19 This observation suggests that, to some extent, the reported percentages were influenced by the framing of the questions. The literature also provided some clue regarding why some patients did not want to discuss costs with their physicians. Zafar et al reported that 34% of patients did not discuss costs with their physicians because, regardless of costs, they wanted to receive the best care possible, 14 suggesting patients' concern that patient-physician cost communication might jeopardize their chance of receiving "the best" treatment. A potential solution is to offer patients the option to discuss costs with other personnel, such as social workers or navigators in the clinic; indeed, Bullock et al observed that 30% of patients preferred discussing costs with someone other than their physicians. 20 Affirming patient-physician cost communication as a critical component of quality cancer care was forwardthinking at the time the ASCO Cost of Cancer Care Task Force released their guidance statement. It is noteworthy that this assertion went largely uncontested over the years. It had been assumed that upfront cost discussions would help patients evaluate the financial implications of their treatment choices to make an informed decision. The limited evidence from the literature suggested that cost communication was associated with better care quality if quantified as patient satisfaction 17 and lower out-ofpocket costs.
14 However, no studies had used a more rigorous study designs (eg, randomized trials or pre-post interventions) to critically evaluate whether patientphysician cost communication would indeed lead to better quality of care or whether the same effect could be achieved by communication between patients and other nonphysician personnel. Also lacking in the literature was a roadmap to assist financially distressed patients when such a need was identified in the cost communication.
Many believe that patient-physician cost communication ultimately could reduce health care costs through minimizing the use of lower value therapies. [26] [27] [28] However, several studies indicated patients with cancer, especially those undergoing active treatment, tended not to be costsensitive. 19, 20, 23 Meisenberg et al reported that only 28% of patients were willing to select the lower cost option when presented with 2 hypothetical treatments that had equal effectiveness but differed in cost. 19 Moreover, Irwin et al observed that, when both out-of-pocket costs and overall costs to the health care system were queried, patients were less sensitive to the societal costs. 10 The results from our current review also suggest that, although oncologists recognize that out-of-pocket costs may affect treatment decisions, many believe that patients should have access to effective treatments regardless of costs. These observations cast doubts on whether patientphysician cost communication can be an effective avenue for reducing overall health care costs.
Two limitations of the current study warrant discussion. First, our inclusion of studies published after August 2009 was based on the assumption that the release of the ASCO Cost of Cancer Care guidance statement would inspire more research on the topic of patient-physician cost communication in oncology. This inclusion criterion should not cause the loss of large amounts of information, because a review article published in 2010 concluded that the topic was "largely understudied." 28 Second, although the vast majority of studies in our review were conducted in the United States, the extent to which the findings summarized here represent the view of American patients with cancer should be explored in future research, because information available in the literature was mostly collected from patients with cancer who had selected characteristics, such as those who were recruited from academic medical centers, carried health insurance, and had an income higher than the median household income in the United States. The larger representation of more affluent patients in those studies is likely associated with a stronger desire to communicate with their physicians on any aspect of their care, including costs. Therefore, it is reasonable to expect that the conclusions from our review may not be generalizable to less affluent subgroups of patients.
Cost communication has grown increasingly important, because patients and physicians are under immense pressure to sustain the affordability of cancer care today. The literature indicated that, although patients and physicians did not object to cost communication, such communication was not frequent. To facilitate effective cost communication, efforts must be made to generate and disseminate accurate, accessible, and transparent cost information. Future research should also use rigorous study designs to explore the effect of cost communication on various dimensions of cancer care quality.
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